الفهرس 
Chronic hepatitis C virus infectionOnly 14 pages are availabe for public view
 |  | from | 122 |  |  |
| | | from | 122 | | |
Abstract
Background: Hepatitis C Virus (HCV) infection is a major global health challenge; it is estimated that more than 80 million people are chronically infected worldwide, with 3–4 million new infections and 350 000 deaths occurring each year because of HCV-related complications.
Aim of the Work: to determine the efficacy of Qurevo-Sovaldi-Ribavirin regimen as a retreatment strategy in NS5A inhibitors (Sofosbuvir & Daclatasvir) resistant patients infected with chronic hepatitis C virus.
Patients and Methods: An observational cross-sectional study was carried out on 20 chronic hepatitis C virus infected patients in The centre of HCV treatment at El Quabary specialized centers in Alexandria where large number of patients receiving their HCV treatment.
Results: all patients (20/20) achieved sustained virological response after 3 months of the last dose of treatment (SVR12).
Conclusion: the new retreatment strategy composed of the triple therapy Qurevo (Ombitasvir/ Paritaprevir/Ritonavir) /Sofosbuvir/ Ribavirin is effective in the treatment of chronic HCV infected patients previously treated with Sofosbuvir/ Daclatasvir/Ribavirin for 12 weeks without achieving sustained virological response (Ns5a inhibitors resistant chronic HCV patients).